Professor Aaron Sverdlov
Director of Heart Failure
School of Medicine and Public Health
- Email:aaron.sverdlov@newcastle.edu.au
- Phone:(02) 4042 0725
Career Summary
Biography
Professor Aaron Sverdlov is a cardiologist and clinician-scientist with proven track record in basic through to clinical research. His research interests encompass a broad spectrum of topics related to heart failure and cardio-oncology (cardiovascular complications of cancer therapies).
Personal statement
I am committed to improving management and outcomes for patients with heart failure through better understanding of mechanisms involved and discovering novel biomarkers and therapies.
Biography
Dr Sverdlov received his medical degree (MBBS) from the University of Adelaide, Australia in 2000. Then he completed his post-graduate training in general medicine and cardiology, including serving as a Chief Medical Resident for 2 years. He was admitted to the Fellowship of the Royal Australasian College of Physicians (FRACP) in December 2007, and then appointed staff specialist in cardiology at the Queen Elizabeth Hospital and Lyell McEwin Hospital from February 2008.
Aaron Sverdlov was awarded his PhD in 2012 from the University of Adelaide under supervision of Prof John Horowitz. His doctoral work was on pathogenesis of aortic valve disease: Aaron led the aortic valve stenosis group at the Queen Elizabeth Hospital and provided the first evidence in humans that progression of aortic stenosis is amenable to treatment with renin-angiotensin-aldosterone system inhibitors. He was then awarded an NHMRC CJ Martin Fellowship, and later AHA Postdoctoral Fellowship to undertake postdoctoral work with Prof WS Colucci at Boston University (2012-15). There he studied mechanisms regulating cardiac function and energetics in models of obesity-induced heart disease. He proved that mitochondrial ROS play a key pathogenic role in metabolic heart disease and identified novel reactive cysteines in mitochondrial complex II that modulate its function and lead to cardiac energetic impairment. He was also involved in describing a new method for quantitation of FDG PET/CT in cardiac sarcoidosis: this work has been heavily cited and this method has been adopted by a number of institutions. Aaron's postdoctoral work gained him a reputation as an expert and leader in mitochondrial redox field.
Upon return to Australia in 2015, in partnership with his wife, Prof Doan Ngo, he established and co-led Cardiometabolic research group as part of the Cardiovascular Program led by Prof John Horowitz at the Basil Hetzel Institute.
Aaron relocated to Newcastle in 2017 where he was appointed Associate Professor and Director of Heart Failure at the University of Newcastle. He has a Clinical Academic appointment as a cardiologist at the John Hunter Hospital and is a Clinical Lead of Heart Failure Services for Hunter New England Local Health District. In December 2022 he was promoted to Professor at the University of Newcastle.
Aaron has been awarded 4-year Heart Foundation Future Leader Fellowship for his research program "Bench-to-bedside approach to improving management and outcomes for patients with heart failure" commencing in January 2018.
Together with Prof Doan Ngo, Aaron has established the first-in-Australia bench-to-bedside "Cancer and the Heart" cardio-oncology program combining basic and clinical research into cancer therapy-related cardiotoxicity with Calvary Mater Newcastle Hospital-based clinical outpatient service. This program is a collaboration between Cancer Network, Cardiology, Oncology, Haematology and Radiation oncology departments and is supported by the grants from the Heart Foundation of Australia, NSW Ministry of Health, Medical Research Futures Fund, Cancer Institute NSW and Hunter Medical Research Institute.
In November 2018, Aaron was a recipient of a Ministerial Award for Rising Stars in Cardiovascular Research.
Research Expertise
Aaron Sverdlov's research encompasses a full spectrum of translation from bench to bedside and service delivery. He has a basic and translational lab at the Hunter Medical Research Institute and shares a research lab with A/Prof Doan Ngo on the Callaghan Campus. His clinical research is at the John Hunter Hospital, Calvary Mater Newcastle and other sites across the Health District.
Broad goals of Aaron's research program are to improve care and health outcomes for patients with heart disease through better understanding of mechanisms responsible for development of heart failure, prevention and early detection of heart disease through development of novel biomarkers and improved delivery of healthcare by dedicated and integrated multidisciplinary approach.
Aaron's specific research interests directions are:
- mechanisms of development of cancer therapy-mediated cardiotoxicity
- development and evaluation of cardio-oncology clinical and translational program
- evaluation of new treatment options for patients with obesity, heart failure and chemotherapy-induced cardiotoxicity
- mechanisms underlying development of heart failure, especially heart failure due to obesity and diabetes
- role of mitochondria and redox stress in heart failure
- role of novel biomarkers in early detection of various forms of heart disease
- development and evaluation of integrated multidisciplinary heart failure service incorporating research and innovation
Across these projects Aaron has a number of local, national and international collaborators.
Track record, peer review and service to the field
Aaron has over 90 career (since 2008) peer-reviewed publications and 4 book chapters (including chapters on Oxidative Stress in Heart Failure in the textbook “Heart Failure: A Companion to Braunwald’s Heart Disease”) with over 2400 citations and has had more than 110 presentations at international and national meetings. He received over 50 competitive grants, with >35 in the last 5 years (total ~$15M AUD).
Aaron Sverdlov serves on the NHMRC's ECF Biomedical Panel (2015-6), NHMRC Cardiovascular Diseases GRP (2016-7) and NHMRC Ideas Grant Panel (2019); Heart Foundation of Australia Future Leader Fellowship (2019, 2022, 2023) and Postdoctoral Fellowships Committees (2017-8); Hunter New England Local Health District TRGS EOI review panel (2017); American Heart Association Cardiac Biology Program Peer Review Committee (2017-9) and Rebecca Cooper Medical Research Foundation grant advisory panel (2016).
He is also a reviewer for the European Society of Cardiology (ESC), Australian Research Council (ARC), Cardiac Society of Australia and New Zealand (CSANZ), Medical Research Council (UK), Croatian Science Foundation, Diabetes Australia, Medical Research Council UK (MRC), Singapore Ministry of Health and Society for Redox Biology and Medicine (SFRBM).
Aaron is an Associate Editor for Heart Lung and Circulation, International Advisor for JACC: CardioOncology and is on editorial board of Hypertension and Frontiers in Cardiovascular Medicine. He is a regular reviewer for multiple leading cardiovascular, pharmacology and basic science journals including Circulation Research, JACC, Hypertension, JMCC, International Journal of Cardiology, Antioxidant Redox Signaling, Cardiovascular Therapeutics and British Journal of Pharmacology.
Teaching and Education
Aaron has been involved in undergraduate teaching in medicine at the University of Newcastle and University of Adelaide as well as Boston University, USA. He supervised numerous clinical students and physician trainees especially in his capacity as the Chief Medical Resident. As a postdoctoral fellow at the Boston University he supervised and mentored honours, PhD and MD/PhD students. Currently he co-supervises 6 PhD, 4 honours students and 3 postdoctoral fellow across University of Newcastle, University of Adelaide and Flinders University of SA. He is involved in professional education of general practitioners and physicians in community and hospital settings.
Collaborations
In addition to multiple collaborations within University of Newcastle, HMRI and Hunter New England Local Health District, Aaron has active research collaborations with University of Adelaide, Flinders University of SA, University of Sydney, Boston University (USA), McMaster University (Canada) and University of East Anglia (UK).
Qualifications
- Doctor of Philosophy, University of Adelaide
- Bachelor of Medicine, Bachelor of Surgery, University of Adelaide
Keywords
- Aortic valve stenosis
- Biomarkers
- Cardio-oncology
- Cardiomyopathy
- Clinical cardiology
- Heart Failure
- Mitochondria
- Obesity and heart disease
- Oxidative stress
Languages
- English (Fluent)
- Russian (Fluent)
Fields of Research
Code | Description | Percentage |
---|---|---|
320507 | Metabolic medicine | 10 |
321199 | Oncology and carcinogenesis not elsewhere classified | 15 |
320101 | Cardiology (incl. cardiovascular diseases) | 75 |
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Director of Heart Failure | University of Newcastle School of Medicine and Public Health Australia |
Academic appointment
Dates | Title | Organisation / Department |
---|---|---|
1/1/2022 - | Co-Director, Newcastle Centre of Excellence in Cardio-Oncology | HMRI Australia |
7/12/2017 - | Fellow - Heart Failure Association (FHFA) of the ESC | Heart Failure Association of the European Society of Cardiology France |
1/11/2015 - | Fellow - American College of Cardiology (FACC) | American College of Cardiology United States |
1/7/2014 - 15/4/2015 | AHA Postdoctoral Fellow | Boston University MA Cardiovascular Medicine United States |
1/1/2013 - | Fellow - European Society of Cardiology (FESC) | European Society of Cardiology France |
1/7/2012 - 22/5/2017 | NHMRC CJ Martin Fellow | University of Adelaide Australia |
1/7/2012 - 15/4/2015 | NHMRC CJ Martin Fellow | Boston University MA Cardiovascular Medicine United States |
1/10/2011 - | Fellow - Cardiac Society of Australia and New Zealand (FCSANZ) | Cardiac Society of Australia and NewZealand Australia |
17/12/2007 - | Fellow - Royal Australasian College of Physicians (FRACP) | The Royal Australasian College of Physicians Australia |
Professional appointment
Dates | Title | Organisation / Department |
---|---|---|
1/1/2018 - | Clinical Lead - "Cancer and the Heart" (Cardio-oncology) program | Hunter New England Area Health Service Australia |
1/7/2017 - | Clinical Lead - Heart Failure Service | Hunter New England Local Health District NSW Health Cardiovascular Medicine Australia |
1/5/2017 - | Clinical Academic Cardiologist | John Hunter Hospital Cardiovascular Medicine Australia |
1/7/2012 - 22/5/2017 | Senior Staff Specialist - Cardiology | Queen Elizabeth Hospital Cardiology Department Australia |
1/2/2008 - 30/6/2012 | Staff Specialist - Cardiology | Queen Elizabeth Hospital Cardiology Department Australia |
Teaching appointment
Dates | Title | Organisation / Department |
---|---|---|
1/1/2005 - 31/12/2006 | Chief Medical Resident | Queen Elizabeth Hospital Department of Medicine Australia |
Awards
Award
Year | Award |
---|---|
2018 |
2018 Ministerial Award for Rising Stars in Cardiovascular Research NSW Health |
Grant Reviews
Year | Grant | Amount |
---|---|---|
2018 |
Singapore Translational Research Investigaor (STaR) Award C3231 - International Govt - Own Purpose - 3231, C3231 - International Govt - Own Purpose - 3231 |
$7,000,000 |
2018 |
Croation Science Foundation (HRZZ) - Project Grant C3232 - International Govt - Other - 3232, C3232 - International Govt - Other - 3232 |
$2,000,000 |
2018 |
NHMRC Project Grant Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
2018 |
MRC Project Grant - Medical Research Council C3232 - International Govt - Other - 3232, C3232 - International Govt - Other - 3232 |
$0 |
2018 |
Heart Foundation Postdoctoral Fellowship Committee Aust Competitive - Non Commonwealth - 1NS, Aust Competitive - Non Commonwealth - 1NS |
$0 |
2018 |
American Heart Association - Cardiac Biology Program Peer Review Committee International - Competitive - 3IFA, International - Competitive - 3IFA |
$0 |
2017 |
NHMRC Cardiovascular GRP Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
2017 |
Heart Foundation Postdoctoral Fellowship Committee Aust Competitive - Non Commonwealth - 1NS, Aust Competitive - Non Commonwealth - 1NS |
$0 |
2017 |
American Heart Association - Cardiac Biology Program Peer Review Committee International - Competitive - 3IFA, International - Competitive - 3IFA |
$0 |
2016 |
NHMRC Cardiovascular GRP Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
2016 |
NHMRC ECF Committee Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
2016 |
Rebecca L Cooper Medical Research Foundation Grant Review Committee Grant - Aust Non Government - 3AFG, Grant - Aust Non Government - 3AFG |
$0 |
2015 |
ARC Discovery Grants Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
2015 |
NHMRC ECF Committee Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Book (1 outputs)
Year | Citation | Altmetrics | Link |
---|---|---|---|
2010 |
Chirkov YY, Sverdlov AL, Horowitz JD, Beneficial effects of perhexiline in cardiovascular disease states (2010) Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatmen... [more] Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline¿s reintroduction into clinical practice. This new book discusses the benefits of perhexiline in the treatment of cardiovascular disease. |
Chapter (2 outputs)
Year | Citation | Altmetrics | Link | ||
---|---|---|---|---|---|
2019 |
Sverdlov A, Ngo D, Colucci W, 'Oxidative stress in heart failure', Heart Failure: A Companion to Braunwald's Heart Disease, Elsevier, Philadelphia, PA 115-126.e6 (2019)
|
||||
2016 | Sawyer DB, Sverdlov AL, Colucci WS, 'Oxidative Stress in Heart Failure', Heart Failure A Companion to Braunwald's Heart Disease, Elsevier, Philadelphia 127-139 (2016) |
Journal article (110 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2024 |
Ray M, Butel-Simoes LE, Lombard JM, Nordman IIC, Van der Westhuizen A, Collins NJ, et al., 'Women's cardiovascular health - the cardio-oncologic jigsaw.', Climacteric, 27 60-67 (2024) [C1]
|
Nova | |||||||||
2024 |
Singleton AC, Redfern J, Diaz A, Koczwara B, Nicholls SJ, Negishi K, et al., 'Integrating CardioOncology Across the Research Pipeline, Policy, and Practice in Australia-An Australian Cardiovascular Alliance Perspective.', Heart Lung Circ, (2024) [C1]
|
||||||||||
2024 |
Balachandran L, Haw TJ, Leong AJW, Croft AJ, Chen D, Kelly C, et al., 'Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic?', Heart Lung Circ, (2024) [C1]
|
||||||||||
2024 |
Litwin SE, Komtebedde J, Seidler T, Borlaug BA, Winkler S, Solomon SD, et al., 'Obesity in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial.', Eur J Heart Fail, 26 177-189 (2024) [C1]
|
Nova | |||||||||
2024 |
Short CE, Rawstorn JC, Jones TL, Edbrooke L, Hayes SC, Maddison R, et al., 'Evaluating a Remotely Delivered Cardio-Oncology Rehabilitation Intervention for Patients With Breast Cancer (REMOTE-COR-B): Protocol for a Single-Arm Feasibility Trial.', JMIR Res Protoc, 13 e53301 (2024)
|
||||||||||
2023 |
Sverdlov AL, Koczwara B, Cehic DA, Clark RA, Hunt L, Nicholls SJ, et al., 'When Cancer and Cardiovascular Disease Intersect: The Challenge and the Opportunity of Cardio-Oncology', Heart Lung and Circulation, (2023) [C1] Cancer and cardiovascular disease (CVD) commonly coexist, with increasing evidence that long-term cancer survivors are more likely to die from CVD than the general population. Eff... [more] Cancer and cardiovascular disease (CVD) commonly coexist, with increasing evidence that long-term cancer survivors are more likely to die from CVD than the general population. Effective management of CVD and its risk factors requires identification of patients at increased risk who may benefit from early intervention and their appropriate monitoring across the disease trajectory. Improving outcomes requires new models of multidisciplinary cancer care supported by care pathways. Such pathways require a clear delineation of the roles and responsibilities of all team members and provision of appropriate enablers for their delivery. These include accessible point-of-care tools/risk calculators, patient resources, and the provision of tailored training opportunities for health care providers.
|
||||||||||
2023 |
Litwin SE, Komtebedde J, Hu M, Burkhoff D, Hasenfuß G, Borlaug BA, et al., 'Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction.', JACC Heart Fail, 11 1103-1117 (2023) [C1]
|
Nova | |||||||||
2023 |
Teske AJ, Moudgil R, López-Fernández T, Barac A, Brown SA, Deswal A, et al., 'Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative.', Circ Cardiovasc Qual Outcomes, 16 e009905 (2023) [C1]
|
Nova | |||||||||
2023 |
Chen D, Untaru R, Stavropoulou G, Assadi-Khansari B, Kelly C, Croft AJ, et al., 'Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)', Journal of Clinical Medicine, 12 2790-2790 [C1]
|
Nova | |||||||||
2023 |
Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al., 'Ferric Carboxymaltose in Heart Failure with Iron Deficiency.', N Engl J Med, 389 975-986 (2023) [C1]
|
||||||||||
2023 |
Fakes K, Williams T, Collins N, Boyle A, Sverdlov AL, Boyes A, Sanson-Fisher R, 'Preparation for cardiac procedures: a cross-sectional study identifying gaps between outpatients' views and experiences of patient-centred care.', Eur Heart J Qual Care Clin Outcomes, (2023) [C1]
|
||||||||||
2023 |
Williams TD, Kaur A, Warner T, Aslam M, Clark V, Walker R, et al., 'Cardiovascular outcomes of cancer patients in rural Australia', Frontiers in Cardiovascular Medicine, 10 (2023) [C1] Background: Cancer and heart disease are the two most common health conditions in the world, associated with high morbidity and mortality, with even worse outcomes in regional are... [more] Background: Cancer and heart disease are the two most common health conditions in the world, associated with high morbidity and mortality, with even worse outcomes in regional areas. Cardiovascular disease is the leading cause of death in cancer survivors. We aimed to evaluate the cardiovascular outcomes of patients receiving cancer treatment (CT) in a regional hospital. Methods: This was an observational retrospective cohort study in a single rural hospital over a ten-year period (17th February 2010 to 19th March 2019). Outcomes of all patients receiving CT during this period were compared to those who were admitted to the hospital without a cancer diagnosis. Results: 268 patients received CT during the study period. High rates of cardiovascular risk factors: hypertension (52.2%), smoking (54.9%), and dyslipidaemia (38.4%) were observed in the CT group. Patients who had CT were more likely to be readmitted with ACS (5.9% vs. 2.8% p = 0.005) and AF (8.2% vs. 4.5% p = 0.006) when compared to the general admission cohort. There was a statistically significant difference observed for all cause cardiac readmission, with a higher rate observed in the CT group (17.1% vs. 13.2% p = 0.042). Patients undergoing CT had a higher rate of mortality (49.5% vs. 10.2%, p = 0.001) and shorter time (days) from first admission to death (401.06 vs. 994.91, p = 0.001) when compared to the general admission cohort, acknowledging this reduction in survival may be driven at least in part by the cancer itself. Conclusion: There is an increased incidence of adverse cardiovascular outcomes, including higher readmission rate, higher mortality rate and shorter survival in people undergoing cancer treatment in rural environments. Rural cancer patients demonstrated a high burden of cardiovascular risk factors.
|
Nova | |||||||||
2023 |
Croft AJ, Kelly C, Chen D, Haw TJ, Sverdlov AL, Ngo DTM, 'Overexpression of Mitochondrial Catalase within Adipose Tissue Does Not Confer Systemic Metabolic Protection against Diet-Induced Obesity.', Antioxidants (Basel), 12 (2023) [C1]
|
Nova | |||||||||
2023 |
Kelly CJ, Chu M, Untaru R, Assadi-Khansari B, Chen D, Croft AJ, et al., 'Association of Circulating Plasma Secreted Frizzled-Related Protein 5 (Sfrp5) Levels with Cardiac Function', Journal of Cardiovascular Development and Disease, 10 274-274 [C1]
|
Nova | |||||||||
2023 |
Yu C, Negishi T, Pathan F, Sverdlov A, Thomas L, Shirazi M, et al., 'Rationale and Design of the Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT): A Pilot Study', Heart Lung and Circulation, (2023) [C1] Background: Cancer therapeutics-related cardiac dysfunction (CTRCD) is a well-recognised complication of cancer treatment. Treatment of CTRCD involves cardioprotective therapy (CP... [more] Background: Cancer therapeutics-related cardiac dysfunction (CTRCD) is a well-recognised complication of cancer treatment. Treatment of CTRCD involves cardioprotective therapy (CPT) which can lead to a recovery of CTRCD with normalisation of the left ventricular ejection fraction (LVEF). As a result, there are potentially millions of cancer survivors with recovered CTRCD on CPT. Cardioprotective therapy can be associated with an undesirable long-term pill burden, financial costs, and side effects. Cancer survivorship is anticipated to increase significantly by the end of this decade. To date, there is no evidence of the safety of stopping CPT in this setting. This study seeks to evaluate the hypothesis that ceasing cardioprotective medication is a feasible and safe option without significant impact on LVEF in low-risk patients who have recovered from CTRCD. Methods and Analysis: We will perform a multicentre prospective open-label randomised controlled trial with blinded endpoint (PROBE) of supervised CPT cessation compared to continuing CPT (control). The primary study end point is the change in LVEF by cardiac magnetic resonance imaging at 6 months of enrolment between the two groups. Secondary end points include changes in quality-of-life questionnaires, other cardiac imaging parameters, and recurrence of heart failure. Conclusion: Cessation Of Pharmacotherapy In Recovered Chemotherapy-induced cardioToxicity (COP-RCT) is one of the first studies currently underway to evaluate the safety of ceasing CPT in recovered CTRCD. The results will inform clinical practice in this evidence-free zone.
|
||||||||||
2023 |
Quirk T, Yao Y, Sverdlov A, Murch S, 'Malignant pericardial effusions: A retrospective look at etiology and prognosis in a tertiary oncological center', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 19 468-472 (2023) [C1]
|
||||||||||
2023 |
Butel-Simoes LE, Haw TJ, Williams T, Sritharan S, Gadre P, Herrmann SM, et al., 'Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.', Hypertension, 80 685-710 (2023) [C1]
|
Nova | |||||||||
2023 |
Lee GA, Aktaa S, Baker E, Gale CP, Yaseen IF, Gulati G, et al., 'European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment', European Heart Journal - Quality of Care and Clinical Outcomes, 9 1-7 (2023) [C1] Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the... [more] Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.
|
Nova | |||||||||
2023 |
McGee M, Shephard L, Sugito S, Baker D, Brienesse S, Al-Omary M, et al., 'Mind The Gap, Aboriginal and Torres Strait Islander Cardiovascular Health: A Narrative Review', Heart Lung and Circulation, 32 136-142 (2023) [C1] Australia's First Nations Peoples, Aboriginal and Torres Strait Islanders, have reduced life expectancy compared to the wider community. Cardiovascular diseases, mainly drive... [more] Australia's First Nations Peoples, Aboriginal and Torres Strait Islanders, have reduced life expectancy compared to the wider community. Cardiovascular diseases, mainly driven by ischaemic heart disease, are the leading contributors to this disparity. Despite over a third of First Nations Peoples living in New South Wales, the bulk of the peer-reviewed literature is from Central Australia and Far North Queensland. Regardless of the site of publication, First Nations Peoples are significantly younger at disease onset and have higher rates of comorbidities, in turn driving adverse health events. On top of this, very few First Nations Peoples specific cardiovascular interventions or programs have been shown to improve outcomes. The traditional biomedical model of care is less efficacious and non-traditional models of communication such as clinical yarning may benefit both clinicians and patients. The key purpose of this review is to highlight the deficiencies of our knowledge of cardiovascular burden of disease for First Nations Peoples; and to serve as a catalyst for more dedicated research. We need to have relationships with communities and concentrate on community improvement and partnerships. By involving First Nations Peoples researchers in collaboration with local communities in all levels of health care design and intervention will improve outcomes.
|
Nova | |||||||||
2023 |
Murtha LA, Hardy SA, Mabotuwana NS, Bigland MJ, Bailey T, Raguram K, et al., 'Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction', Scientific Reports, 13 (2023) [C1] Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural int... [more] Despite the high prevalence of heart failure in the western world, there are few effective treatments. Fibulin-3 is a protein involved in extracellular matrix (ECM) structural integrity, however its role in the heart is unknown. We have demonstrated, using single cell RNA-seq, that fibulin-3 was highly expressed in quiescent murine cardiac fibroblasts, with expression highest prior to injury and late post-infarct (from ~ day-28 to week-8). In humans, fibulin-3 was upregulated in left ventricular tissue and plasma of heart failure patients. Fibulin-3 knockout (Efemp1 -/-) and wildtype mice were subjected to experimental myocardial infarction. Fibulin-3 deletion resulted in significantly higher rate of cardiac rupture days 3¿6 post-infarct, indicating a weak and poorly formed scar, with severe ventricular remodelling in surviving mice at day-28 post-infarct. Fibulin-3 knockout mice demonstrated less collagen deposition at day-3 post-infarct, with abnormal collagen fibre-alignment. RNA-seq on day-3 infarct tissue revealed upregulation of ECM degradation and inflammatory genes, but downregulation of ECM assembly/structure/organisation genes in fibulin-3 knockout mice. GSEA pathway analysis showed enrichment of inflammatory pathways and a depletion of ECM organisation pathways. Fibulin-3 originates from cardiac fibroblasts, is upregulated in human heart failure, and is necessary for correct ECM organisation/structural integrity of fibrotic tissue to prevent cardiac rupture post-infarct.
|
Nova | |||||||||
2022 |
Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, et al., 'Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.', Lancet, 399 1130-1140 (2022) [C1]
|
Nova | |||||||||
2022 |
Harris ML, Egan N, Forder PM, Bateson D, Sverdlov AL, Murphy VE, Loxton D, 'Patterns of contraceptive use among young Australian women with chronic disease: findings from a prospective cohort study', Reproductive Health, 19 (2022) [C1] Background: Given chronic disease is increasing among young women and unintended pregnancies among these women are associated with poor maternal and fetal outcomes, these women wo... [more] Background: Given chronic disease is increasing among young women and unintended pregnancies among these women are associated with poor maternal and fetal outcomes, these women would benefit from effective preconception care. However, there is a lack of understanding of how these women use or don¿t use contraception to inform such interventions. This study examined patterns of contraceptive use among an Australian cohort of young women and investigated the influence of chronic disease on contraceptive use over time. Methods: Using data from 15,244 young women from the Australian Longitudinal Study on Women¿s Health (born 1989¿1995), latent transition analysis was performed to identify distinct contraceptive patterns among women who were at risk of an unintended pregnancy. Multinomial mixed-effect models were used to evaluate the relationship between contraceptive combinations and chronic disease. Results: Contraceptive use for women with cardiac and autoinflammatory diseases differed to women without chronic disease over the observation period. Compared to women without chronic disease using the pill, women with cardiac disease had double the odds of using ¿other¿ contraception and condoms (OR = 2.20, 95% CI 1.34, 3.59) and a modest increase in the odds of using the combined oral contraceptive pill and condoms (OR = 1.39, 95% CI 1.03, 1.89). Compared to women without chronic disease who used the pill, women with autoinflammatory disease had increased odds of using LARC and condoms (OR = 1.58, 95% CI 1.04, 2.41), using ¿other¿ contraception and condoms (OR = 1.69, 95% CI 1.11, 2.57), and using the¿combined oral contraceptive pill and condoms (OR = 1.38, 95% CI 1.09, 1.75). No differences in contraceptive patterns over the observation period were found for women with asthma or diabetes when compared to women without chronic disease. Conclusion: The findings identified a need for effective contraceptive counselling as part of routine chronic disease care and improved communication between health¿care providers and women with chronic disease to improve young women¿s contraceptive knowledge and agency in contraceptive choice, particularly for those with cardiac or autoinflammatory conditions. This may be the key to reducing high-risk unintended pregnancies among this vulnerable population.
|
Nova | |||||||||
2022 |
Sindone AP, De Pasquale C, Amerena J, Burdeniuk C, Chan A, Coats A, et al., 'Consensus statement on the current pharmacological prevention and management of heart failure', MEDICAL JOURNAL OF AUSTRALIA, 217 212-217 (2022) [C1]
|
Nova | |||||||||
2022 |
Collins N, Sugito S, Davies A, Boyle A, Sverdlov A, Attia J, et al., 'Prevalence and survival associated with pulmonary hypertension after mitral valve replacement: National echocardiography database of Australia study', PULMONARY CIRCULATION, 12 (2022) [C1]
|
Nova | |||||||||
2022 |
White J, Byles J, Williams T, Untaru R, Ngo DTM, Sverdlov AL, 'Early access to a cardio-oncology clinic in an Australian context: a qualitative exploration of patient experiences', CARDIO-ONCOLOGY, 8 (2022) [C1]
|
Nova | |||||||||
2022 |
Verma S, Dhingra NK, Butler J, Anker SD, Ferreira JP, Filippatos GS, et al., 'Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial', The Lancet Diabetes and Endocrinology, 10 35-45 (2022) [C1] Background: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treat... [more] Background: It is important to evaluate whether a new treatment for heart failure with reduced ejection fraction (HFrEF) provides additive benefit to background foundational treatments. As such, we aimed to evaluate the efficacy and safety of empagliflozin in patients with HFrEF in addition to baseline treatment with specific doses and combinations of disease-modifying therapies. Methods: We performed a post-hoc analysis of the EMPEROR-Reduced randomised, double-blind, parallel-group trial, which took place in 520 centres (hospitals and medical clinics) in 20 countries in Asia, Australia, Europe, North America, and South America. Patients with New York Heart Association (NYHA) classification II¿IV with an ejection fraction of 40% or less were randomly assigned (1:1) to receive the addition of either oral empagliflozin 10 mg per day or placebo to background therapy. The primary composite outcome was cardiovascular death and heart failure hospitalisation; the secondary outcome was total heart failure hospital admissions. An extended composite outcome consisted of inpatient and outpatient HFrEF events was also evaluated. Outcomes were analysed according to background use of angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs) or angiotensin receptor neprilysin inhibitors (ARNIs), as well as ß blockers and mineralocorticoid receptor antagonists (MRAs) at less than 50% or 50% or more of target doses and in various combinations. This study is registered with ClinicalTrials.gov, NCT03057977. Findings: In this post-hoc analysis of 3730 patients (mean age 66·8 years [SD 11·0], 893 [23·9%] women; 1863 [49·9%] in the empagliflozin group, 1867 [50·1%] in the placebo group) assessed between March 6, 2017, and May 28, 2020, empagliflozin reduced the risk of the primary outcome (361 in 1863 participants in the empagliflozin group and 462 of 1867 in the placebo group; HR 0·75 [95% CI 0·65¿0·86]) regardless of background therapy or its target doses for ACE inhibitors or ARBs at doses of less than 50% of the target dose (HR 0·85 [0·69¿1·06]) and for doses of 50% or more of the target dose (HR 0·67 [0·52¿0·88]; pinteraction=0·18). A similar result was seen for ß blockers at doses of less than 50% of the target dose (HR 0·66 [0·54¿0·80]) and for doses of 50% or more of the target dose (HR 0·81 [0·66¿1·00]; pinteraction=0·15). Empagliflozin also reduced the risk of the primary outcome irrespective of background use of triple therapy with an ACE inhibitor, ARB, or ARNI plus ß blocker plus MRA (given combination HR 0·73 [0·61¿0·88]; not given combination HR 0·76 [0·62¿0·94]; pinteraction=0·77). Similar patterns of benefit were observed for the secondary and extended composite outcomes. Empagliflozin was well tolerated and rates of hypotension, symptomatic hypotension, and hyperkalaemia were similar across all subgroups. Interpretation: Empagliflozin reduced serious heart failure outcomes across doses and combinations of disease-modifying therapies for HFrEF. Clinically, these data suggest that empagliflozin might be considered as a foundational therapy in patients with HFrEF regardless of their existing background therapy. Funding: Boehringer Ingelheim and Eli Lilly and Company.
|
||||||||||
2022 |
McGee MJ, Ray M, Brienesse SC, Sritharan S, Boyle AJ, Jackson N, et al., 'Remote monitoring in patients with heart failure with cardiac implantable electronic devices: A systematic review and meta-analysis', Open Heart, 9 (2022) [C1] Background Remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) is now the standard of care, but whether the demonstrated benefits of RM translate into improve... [more] Background Remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) is now the standard of care, but whether the demonstrated benefits of RM translate into improvements in heart failure (HF) management is controversial. This systematic review addresses the role of RM in patients with HF with a CIED. Methods and results A systematic search of the literature for randomised clinical trials in patients with HF and a CIED assessing efficacy/effectiveness of RM was performed using MEDLINE, PubMed and Embase. Meta-analysis was performed on the effects of RM of CIEDs in patients with HF on mortality and readmissions. Effects on implantable cardiac defibrillator (ICD) therapy, healthcare costs and clinic presentations were also assessed. 607 articles were identified and refined to 10 studies with a total of 6579 patients. Implementation of RM was not uniform with substantial variation in methodology across the studies. There was no reduction in mortality or hospital readmission rates, while ICD therapy findings were inconsistent. There was a reduction in patient-associated healthcare costs and reduction in healthcare presentations. Conclusion RM for patients with CIEDs and HF was not uniformly performed. As currently implemented, RM does not provide a benefit on overall mortality or the key metric of HF readmission. It does provide a reduction in healthcare costs and healthcare presentations. PROSPERO REGISTRATION NUMBER CRD42019129270.
|
Nova | |||||||||
2022 |
Dee F, Savage L, Leitch JW, Collins N, Loten C, Fletcher P, et al., 'Management of Acute Coronary Syndromes in Patients in Rural Australia The MORACS Randomized Clinical Trial', JAMA CARDIOLOGY, 7 690-698 (2022) [C1]
|
Nova | |||||||||
2022 |
Al-Omary MS, Majeed T, Al-Khalil H, Sugito S, Clapham M, Ngo DTM, et al., 'Patient characteristics, short-term and long-term outcomes after incident heart failure admissions in a regional Australian setting', Open Heart, 9 (2022) [C1] Aims This study aims to (1) define the characteristics of patients with a first admission for heart failure (HF), stratified by type (reduced (HFrEF) vs preserved (HFpEF) ejection... [more] Aims This study aims to (1) define the characteristics of patients with a first admission for heart failure (HF), stratified by type (reduced (HFrEF) vs preserved (HFpEF) ejection fraction) in a regional Australian setting; (2) compare the outcomes in terms of mortality and rehospitalisation and (3) assess adherence to the treatment guidelines. Methods We identified all index hospitalisations with HF to John Hunter Hospital and Tamworth Rural Referral Hospital in the Hunter New England Local Health District over a 12 months. We used the recent Australian HF guidelines to classify HFrEF and HFpEF and assess adherence to guideline-directed therapy. The primary outcome of the study was to compare short-term (1 year) and long-term all-cause mortality and the composite of all-cause hospitalisation or all-cause mortality of patients with HFrEF and HFpEF. Results There were 664 patients who had an index HF admission to John Hunter and Tamworth hospitals in 2014. The median age was 80 years, 47% were female and 22 (3%) were Aboriginal. In terms of HF type, 29% had HFrEF, 37% had HFpEF, while the remainder (34%) did not have an echocardiogram within 1 year of admission and could not be classified. The median follow-up was 3.3 years. HFrEF patients were predominantly male (64%) and in 48% the aetiology was ischaemic heart disease. The 1-year all-cause mortality was 23% in HFpEF subgroup and 29% in HFrEF subgroup (p=0.15). Five-year mortality was 61% in HFpEF and HFrEF patients. Of the HFrEF patients, only 61% were on renin-angiotensin-aldosterone blockers, 74% were on ß-blockers and 39% were on aldosterone antagonist. Conclusion HF patients are elderly and about evenly split between HFrEF and HFpEF. In this regional cohort, both HF types are associated with similar 1-year and 5-year mortality following incident HF hospitalisation. Echocardiography and guideline-directed therapies were underused.
|
Nova | |||||||||
2022 |
Awan FT, Addison D, Alfraih F, Baratta SJ, Campos RN, Cugliari MS, et al., 'International consensus statement on the management of cardiovascular risk of Bruton?s tyrosine kinase inhibitors in CLL', BLOOD ADVANCES, 6 5516-5525 (2022) [C1]
|
Nova | |||||||||
2021 |
Ferreira D, Graffen S, Watkins B, Peters B, Lim GJ, Kamalanathan H, et al., 'Effects of lockdown on acute coronary syndrome incidence in an area without community transmission of COVID-19', Open Heart, 8 (2021) [C1] Objective To assess the changes in cardiac hospitalisations, acute coronary syndromes (ACS) and out-of-hospital cardiac arrest (OOHCA) during COVID-19 isolation compared with prio... [more] Objective To assess the changes in cardiac hospitalisations, acute coronary syndromes (ACS) and out-of-hospital cardiac arrest (OOHCA) during COVID-19 isolation compared with prior time periods in an area of low COVID-19 disease incidence. Methods Review of all cardiology admissions, non-ST segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI) requiring urgent catheter laboratory activation and OOHCA. The 10-week period of government-imposed social isolation (23 March-31 May 2020) was compared with the same period in 2018, 2019 and a 10-week period prior to social isolation (6 January-15 March 2020). Incidence rate ratios were calculated. Symptom to balloon time was also compared for those requiring catheterisation laboratory activation for STEMI. Results The incidence of COVID-19 in the health district was 0.14 per 100 000 per day during the isolation period. There was a significant reduction in cardiology hospitalisations, NSTEMI and STEMI presentations without changes in OOHCA or symptom to balloon time for STEMI. Conclusions We observed a significant decline in cardiology presentations during social isolation without widespread COVID-19 disease. This provides further evidence for the important influence of social and behavioural factors on coronary event rates.
|
Nova | |||||||||
2021 |
Cehic DA, Sverdlov AL, Koczwara B, Emery J, Ngo DTM, Thornton-Benko E, 'The Importance of Primary Care in Cardio-Oncology', CURRENT TREATMENT OPTIONS IN ONCOLOGY, 22 (2021) [C1]
|
Nova | |||||||||
2021 |
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al., 'Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure', NEW ENGLAND JOURNAL OF MEDICINE, 384 105-116 (2021) [C1]
|
||||||||||
2021 |
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Boehm M, et al., 'Empagliflozin in Heart Failure with a Preserved Ejection Fraction', NEW ENGLAND JOURNAL OF MEDICINE, 385 1451-1461 (2021) [C1]
|
||||||||||
2021 |
Chen D, Kelly C, Haw TJ, Lombard JM, Nordman IIC, Croft AJ, et al., 'Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers', Current Heart Failure Reports, 18 362-377 (2021) [C1] Purpose of Review: Breast cancer survival rate has greatly improved in the last two decades due to the emergence of next-generation anti-cancer agents. However, cardiotoxicity rem... [more] Purpose of Review: Breast cancer survival rate has greatly improved in the last two decades due to the emergence of next-generation anti-cancer agents. However, cardiotoxicity remains a significant adverse effect arising from traditional and emerging chemotherapies as well as targeted therapies for breast cancer patients. In this review, we will discuss cardiotoxicities of both traditional and emerging therapies for breast cancer. We will discuss current practices to detect cardiotoxicity of these therapies with the focus on new and emerging biomarkers. We will then focus on ¿omics approaches, especially the use of epigenetics to discover novel biomarkers and therapeutics to mitigate cardiotoxicity. Recent Findings: Significant cardiotoxicities of conventional chemotherapies remain and new and unpredictable new forms of cardiac and/or vascular toxicity emerge with the surge in novel and targeted therapies. Yet, there is no clear guidance on detection of cardiotoxicity, except for significant left ventricular systolic dysfunction, and even then, there is no uniform definition of what constitutes cardiotoxicity. The gold standard for detection of cardiotoxicity involves a serial echocardiography in conjunction with blood-based biomarkers to detect early subclinical cardiac dysfunction. However, the ability of these tests to detect early disease remains limited and not all forms of toxicity are detectable with these modalities. Summary: There is an unprecedented need to discover novel biomarkers that are sensitive and specific for early detection of subclinical cardiotoxicity. In that space, novel echocardiographic techniques, such as strain, are becoming more common-place and new biomarkers, discovered by epigenetic approaches, seem to become promising alternatives or adjuncts to conventional non-specific cardiac biomarkers.
|
Nova | |||||||||
2021 |
Ell P, Martin JM, Cehic DA, Ngo DTM, Sverdlov AL, 'Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation', Current Treatment Options in Oncology, 22 (2021) [C1] Radiation therapy is a key component of modern-day cancer therapy and can reduce the rates of recurrence and death from cancer. However, it can increase risk of cardiovascular (CV... [more] Radiation therapy is a key component of modern-day cancer therapy and can reduce the rates of recurrence and death from cancer. However, it can increase risk of cardiovascular (CV) events, and our understanding of the timeline associated with that risk is shorter than previously thought. Risk mitigation strategies, such as different positioning techniques, and breath hold acquisitions as well as baseline cardiovascular risk stratification that can be undertaken at the time of radiotherapy planning should be implemented, particularly for patients receiving chest radiation therapy. Primary and secondary prevention of cardiovascular disease (CVD), as appropriate, should be used before, during, and after radiation treatment in order to minimize the risks. Opportunistic screening for subclinical coronary disease provides an attractive possibility for primary/secondary CVD prevention and thus mitigation of long-term CV risk. More data on long-term clinical usefulness of this strategy and development of appropriate management pathways would further strengthen the evidence for the implementation of such screening. Clear guidelines in initial cardiovascular screening and cardiac aftercare following radiotherapy need to be formulated in order to integrate these measures into everyday clinical practice and policy and subsequently improve post-treatment morbidity and mortality for these patients.
|
Nova | |||||||||
2021 |
McGee M, Sugito S, Al-Omary MS, Hartnett D, Senanayake T, Hales K, et al., 'Heart failure outcomes in Aboriginal and Torres Strait Islander peoples in the Hunter New England region of New South Wales', INTERNATIONAL JOURNAL OF CARDIOLOGY, 334 65-71 (2021) [C1]
|
Nova | |||||||||
2020 |
Ngo DTM, Williams T, Horder S, Kritharides L, Vardy J, Mandaliya H, et al., 'Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab', JOURNAL OF CLINICAL MEDICINE, 9 (2020) [C1]
|
Nova | |||||||||
2020 |
Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al., 'Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society', European Journal of Heart Failure, 22 1945-1960 (2020) [C1] This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncolog... [more] This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
|
Nova | |||||||||
2020 |
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al., 'Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure', NEW ENGLAND JOURNAL OF MEDICINE, 383 1413-1424 (2020)
|
||||||||||
2020 |
Al-Omary MS, Sugito S, Boyle AJ, Sverdlov AL, Collins NJ, 'Pulmonary Hypertension Due to Left Heart Disease', HYPERTENSION, 75 1397-1408 (2020) [C1]
|
Nova | |||||||||
2020 |
Untaru R, Chen D, Kelly C, May A, Collins NJ, Leitch J, et al., 'Suboptimal Use of Cardioprotective Medications in Patients With a History of Cancer', JACC: CARDIOONCOLOGY, 2 312-315 (2020) [C1]
|
Nova | |||||||||
2020 |
Diaz A, Sverdlov AL, Kelly B, Ngo DTM, Bates N, Garvey G, 'Nexus of cancer and cardiovascular disease for Australia's first peoples', Journal of Global Oncology, 2020 115-119 (2020) [C1]
|
Nova | |||||||||
2019 |
Murtha L, Morten M, Schuliga M, Mabotuwana N, Hardy S, Waters D, et al., 'The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis', Aging and Disease, 10 419-428 (2019) [C1]
|
Nova | |||||||||
2019 |
Gopal DM, Ayalon N, Wang Y-C, Siwik D, Sverdlov A, Donohue C, et al., 'Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 8 (2019) [C1]
|
Nova | |||||||||
2019 |
Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ, 'Ibrutinib-related atrial fibrillation: A single center Australian experience', Asia-Pacific Journal of Clinical Oncology, 15 e187-e190 (2019) [C1] Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of arrhythmia are variable in different studies. Th... [more] Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of arrhythmia are variable in different studies. The aim of the current analysis was to evaluate the incidence of AF in a single-center cohort of patients. Methods: This analysis was conducted at Hunter New England Local Health District, Australia between April 1, 2015 and June 30, 2017. We included all consecutive patients commenced on ibrutinib for hematological malignancies. Patients with a history of paroxysmal AF were excluded. The primary end point was incidence of AF. Time to diagnosis and management were secondary outcomes of interest. Results: A total of 24 patients (age 73¿±¿9 years, males n¿=¿16 [67%]) were commenced on ibrutinib treatment during the study period with chronic lymphocytic leukemia (n¿=¿21, 88%) as the main indication. During a median follow-up of 12 months, four (17%) patients were diagnosed with AF with increasing age, duration of ibrutinib treatment as associations. The median time to AF diagnosis was 9 (interquartile range [IQR]: 7-18) months. All patients were managed with a rate control strategy with beta blockers as the preferred agents. Three (75%) patients were commenced on anticoagulation for stroke prevention. During a follow-up of 18 (IQR: 17-23) months following AF onset, one patient required hospitalization for AF. There were no bleeding complications reported. Conclusions: In conclusion, this series noted a higher incidence of AF than previously reported. Oncologists and cardiologists need to be aware of the increased risk of AF in patients receiving ibrutinib.
|
Nova | |||||||||
2019 |
Ngo DTM, Sverdlov AL, Karki S, Macartney-Coxson D, Stubbs RS, Farb MG, et al., 'Oxidative modifications of mitochondrial complex ii are associated with insulin resistance of visceral fat in obesity', American Journal of Physiology - Endocrinology and Metabolism, 316 E168-E177 (2019) [C1] Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been suggested as mechanisms of insulin resistanc... [more] Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been suggested as mechanisms of insulin resistance. The mechanism(s) behind this remains incompletely understood. In this study, we hypothesized that mitochondrial complex II dysfunction plays a role in impaired insulin sensitivity in visceral adipose tissue of subjects with obesity. We obtained subcutaneous and visceral adipose tissue biopsies from 43 subjects with obesity (body mass index = 30 kg/m 2 ) during planned bariatric surgery. Compared with subcutaneous adipose tissue, visceral adipose tissue exhibited decreased complex II activity, which was restored with the reducing agent dithiothreitol (5 mM) (P < 0.01). A biotin switch assay identified that cysteine oxidative posttranslational modifications (OPTM) in complex II subunit A (succinate dehydrogenase A) were increased in visceral vs. subcutaneous fat (P < 0.05). Insulin treatment (100 nM) stimulated complex II activity in subcutaneous fat (P < 0.05). In contrast, insulin treatment of visceral fat led to a decrease in complex II activity (P < 0.01), which was restored with addition of the mitochondria-specific oxidant scavenger mito-TEMPO (10 µ M). In a cohort of 10 subjects with severe obesity, surgical weight loss decreased OPTM and restored complex II activity, exclusively in the visceral depot. Mitochondrial complex II may be an unrecognized and novel mediator of insulin resistance associated with visceral adiposity. The activity of complex II is improved by weight loss, which may contribute to metabolic improvements associated with bariatric surgery.
|
Nova | |||||||||
2019 |
Luptak I, Qin F, Sverdlov AL, Pimentel DR, Panagia M, Croteau D, et al., 'Energetic dysfunction is mediated by mitochondrial reactive oxygen species and precedes structural remodeling in metabolic heart disease', Antioxidants and Redox Signaling, 31 539-549 (2019) [C1] Aims: Metabolic syndrome is associated with metabolic heart disease (MHD) that is characterized by left ventricular (LV) hypertrophy, interstitial fibrosis, contractile dysfunctio... [more] Aims: Metabolic syndrome is associated with metabolic heart disease (MHD) that is characterized by left ventricular (LV) hypertrophy, interstitial fibrosis, contractile dysfunction, and mitochondrial dysfunction. Overexpression of catalase in mitochondria (transgenic expression of catalase targeted to the mitochondria [mCAT]) prevents the structural and functional features of MHD caused by a high-fat, high-sucrose (HFHS) diet for =4 months. However, it is unclear whether the effect of mCAT is due to prevention of reactive oxygen species (ROS)-mediated cardiac remodeling, a direct effect on mitochondrial function, or both. To address this question, we measured myocardial function and energetics in mice, with or without mCAT, after 1 month of HFHS, before the development of cardiac structural remodeling. Results: HFHS diet for 1 month had no effect on body weight, heart weight, LV structure, myocyte size, or interstitial fibrosis. Isolated cardiac mitochondria from HFHS-fed mice produced 2.2- to 3.8-fold more H2O2, and 16%-29% less adenosine triphosphate (ATP). In isolated beating hearts from HFHS-fed mice, [phosphocreatine (PCr)] and the free energy available for ATP hydrolysis (¿G~ATP) were decreased, and they failed to increase with work demands. Overexpression of mCAT normalized ROS and ATP production in isolated mitochondria, and it corrected myocardial [PCr] and ¿G~ATP in the beating heart. Innovation: This is the first demonstration that in MHD, mitochondrial ROS mediate energetic dysfunction that is sufficient to impair contractile function. Conclusion: ROS produced and acting in the mitochondria impair myocardial energetics, leading to slowed relaxation and decreased contractile reserve. These effects precede structural remodeling and are corrected by mCAT, indicating that ROS-mediated energetic impairment, per se, is sufficient to cause contractile dysfunction in MHD.
|
Nova | |||||||||
2018 |
Luptak I, Sverdlov AL, Panagia M, Qin F, Pimentel DR, Croteau D, et al., 'Decreased ATP production and myocardial contractile reserve in metabolic heart disease.', Journal of molecular and cellular cardiology, 116 106-114 (2018) [C1]
|
Nova | |||||||||
2018 |
Efird JT, Jindal C, Kiser AC, Akhter SA, Crane PB, Kypson AP, et al., 'Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents', Journal of International Medical Research, 46 3183-3194 (2018) [C1] Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patien... [more] Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT). Administration of nitrates with antiplatelet agents reduces the conversion rate of cyclic guanosine monophosphate to guanosine monophosphate. This process is associated with increased concentrations of free radicals, catecholamines, and blood plasma volume. We hypothesized that patients undergoing CABG surgery who receive PINOT may be more susceptible to POAF when nitrates are administered with antiplatelet agents. Methods: Clinical records were examined from a prospectively maintained cohort of 4,124 patients undergoing primary isolated CABG surgery to identify POAF-associated factors. Results: POAF risk was increased among patients receiving PINOT, and the greatest effect was observed when nitrates were administered with antiplatelet therapy. Adjustment for comorbidities did not substantively change the study results. Conclusions: Administration of nitrates with certain antiplatelet agents was associated with an increased POAF risk among patients undergoing CABG surgery. Additional studies are needed to determine whether preventive strategies such as administration of antioxidants will reduce this risk.
|
Nova | |||||||||
2018 |
Al-Omary MS, Khan AA, Davies AJ, Fletcher PJ, Mcivor D, Bastian B, et al., 'Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014.', ESC heart failure, 5 271-278 (2018) [C1]
|
Nova | |||||||||
2017 |
Amarasekera AT, Assadi-Khansari B, Liu S, Black M, Dymmott G, Rogers NM, et al., 'Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults', PLOS ONE, 12 (2017) [C1]
|
||||||||||
2016 |
Miller EJ, Calamaras T, Elezaby A, Sverdlov A, Qin F, Luptak I, et al., 'Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016) [C1]
|
||||||||||
2016 |
Sverdlov AL, Elezaby A, Qin F, Behring JB, Luptak I, Calamaras TD, et al., 'Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart Disease', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016) [C1]
|
||||||||||
2016 |
Amarasekera AT, Sverdlov AL, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients', Diabetes and Metabolism, 42 378-381 (2016) [C1]
|
Nova | |||||||||
2015 |
Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, et al., 'High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 78 165-173 (2015) [C1]
|
||||||||||
2015 |
Yao C, Behring JB, Shao D, Sverdlov AL, Whelan SA, Elezaby A, et al., 'Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins', PLOS ONE, 10 (2015) [C1]
|
||||||||||
2015 |
Horowitz JD, Chong C-R, Ngo DT, Sverdlov AL, 'Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?', JOURNAL OF THORACIC DISEASE, 7 E607-E611 (2015)
|
||||||||||
2015 |
Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, et al., 'Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 79 275-283 (2015) [C1]
|
||||||||||
2014 |
Procter NEK, Chong C-R, Sverdlov AL, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics', SEMINARS IN THROMBOSIS AND HEMOSTASIS, 40 660-668 (2014)
|
||||||||||
2014 |
Chong C-R, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, et al., 'Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes', CARDIOVASCULAR DRUGS AND THERAPY, 28 347-360 (2014)
|
||||||||||
2014 |
Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al., 'Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis', JOURNAL OF NUCLEAR CARDIOLOGY, 21 925-939 (2014)
|
||||||||||
2014 |
Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of the Nitric Oxide System: Are We as Old as Our NO?', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (2014)
|
||||||||||
2013 |
Chan WPA, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, et al., 'Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome', AMERICAN JOURNAL OF MEDICINE, 126 (2013) [C1]
|
||||||||||
2013 |
Maher AR, Arif S, Madhani M, Abozguia K, Ahmed I, Fernandez BO, et al., 'Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite', BRITISH JOURNAL OF PHARMACOLOGY, 169 659-670 (2013) [C1]
|
||||||||||
2013 |
Sverdlov AL, Chan WPA, Procter NEK, Chirkov YY, Ngo DTM, Horowitz JD, 'Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy', INTERNATIONAL JOURNAL OF CARDIOLOGY, 168 4624-4630 (2013)
|
||||||||||
2013 |
Ngo DTM, Horowitz JD, Sverdlov AL, 'Heart Failure A Corin-Deficient State?', HYPERTENSION, 61 284-285 (2013)
|
||||||||||
2013 |
Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, et al., 'Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?', CARDIOVASCULAR DRUGS AND THERAPY, 27 541-547 (2013)
|
||||||||||
2013 |
Dautov RF, Ngo DTM, Licari G, Liu S, Sverdlov AL, Ritchie RH, et al., 'The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 35 72-78 (2013)
|
||||||||||
Show 107 more journal articles |
Conference (44 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2023 |
Chen D, Croft A, Haw TJ, Kelly C, Leong A, Sverdlov A, Ngo D, 'The clinically active PARP inhibitor olaparib ameliorates doxorubicin-induced cardiotoxicity in both in vitro and in vivo model', EUROPEAN HEART JOURNAL, NETHERLANDS, Amsterdam (2023)
|
|||||||
2023 |
Williams T, Collins N, Boyle A, Sverdlov A, Boyes A, Sanson-Fisher R, 'Preparation for cardiac catheterisation: patient endorsement and experiences of patientcentred care', PATIENT EDUCATION AND COUNSELING (2023)
|
|||||||
2023 |
Janssen H, Hasnain M, Owen S, Brown A, Smallwood R, Usher K, et al., 'Evidence for the use of co-design with Aboriginal and/or Torres Strait Islander People to strengthen cardiovascular health: A scoping review', INTERNATIONAL JOURNAL OF STROKE (2023)
|
|||||||
2014 | Sverdlov AL, Elezaby A, Qin F, Behring JB, Bachschmid MM, Luptak I, et al., 'Oxidative Protein Modifications Mediate Mitochondrial Dysfunction in Metabolic Heart Disease: Correction ex vivo and in vivo', CIRCULATION (2014) | |||||||
2014 | Luptak I, Sverdlov AL, Elezaby A, Miller EJ, Pimentel DR, Liesa M, et al., 'Western Diet for One Month Impairs Myocardial Energetics and Both Systolic and Diastolic Pump Function in the Mouse Heart', CIRCULATION (2014) | |||||||
2014 | Elezaby A, Sverdlov AL, Tu VH, Qin F, Rimer J, Schaffer JE, et al., 'Metabolic Remodeling in Mice with Cardiomyocyte-Specific Fatty Acid Overload', CIRCULATION (2014) | |||||||
2013 | Elezaby A, Sverdlov A, Tu V, Soni K, Liesa M, Liesa M, et al., 'Impairment of the PPARa/PGC1a Axis Compromises Mitochondrial Biogenesis and Function in Hearts With Cardiomyocyte-Specific Fatty Acid Transport Protein 1 (FATP1) Overexpression', CIRCULATION, Dallas, TX (2013) | |||||||
2013 |
Amarasekera AT, Sverdlov AL, Roberts MS, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations; independent of vitamin D status', EUROPEAN HEART JOURNAL, Amsterdam, NETHERLANDS (2013)
|
|||||||
Show 41 more conferences |
Preprint (5 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2023 |
Fakes K, Williams T, Collins N, Boyle A, Sverdlov A, Boyes A, Sanson-Fisher R, 'Preparation for cardiac procedures: identifying gaps between outpatients views and experiences of patient-centred care (2023)
|
|||||||
2023 |
Murtha L, Hardy S, Mabotuwana N, Bigland M, Bailey T, Raguram K, et al., 'Fibulin-3 is necessary to prevent cardiac rupture following myocardial infarction (2023)
|
|||||||
2023 |
Ferreira D, Mikhail P, Lim J, Ray M, Dwivedi J, Brienesse S, et al., 'Manual Chest PRESSURE during Direct Current Cardioversion for Atrial Fibrillation: A Randomised Control Trial (PRESSURE-AF) (2023)
|
|||||||
Show 2 more preprints |
Grants and Funding
Summary
Number of grants | 72 |
---|---|
Total funding | $18,682,086 |
Click on a grant title below to expand the full details for that specific grant.
20243 grants / $60,035
HMRI Foundation Research Team Excellence Award 2023$30,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Doan Ngo, Professor Aaron Sverdlov |
Scheme | HMRI Research Excellence Award |
Role | Investigator |
Funding Start | 2024 |
Funding Finish | 2024 |
GNo | G2400579 |
Type Of Funding | Scheme excluded from IGS |
Category | EXCL |
UON | Y |
Pre-clinical testing of mitochondrial-targeted antioxidant SS-31 to simultaneously treat colorectal cancer and associated cardiac cachexia $18,430
Funding body: Hunter New England Local Health District
Funding body | Hunter New England Local Health District |
---|---|
Project Team | Professor Aaron Sverdlov, Ms Amanda Croft |
Scheme | John Hunter Hospital Charitable Trust Grant |
Role | Lead |
Funding Start | 2024 |
Funding Finish | 2024 |
GNo | G2400587 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Beyond anthracyclines and trastuzumab: Cardiotoxicity of newer targeted agents in Breast Cancer$11,605
Funding body: Novartis Pharmaceuticals Australia Pty Limited
Funding body | Novartis Pharmaceuticals Australia Pty Limited |
---|---|
Project Team | Prof AL Sverdlov, Prof DTM Ngo |
Scheme | Unrestricted Educational Grant |
Role | Lead |
Funding Start | 2024 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | N |
20236 grants / $3,811,551
Using polygenic scores to guide the treatment and prophylaxis of hypertension$2,695,331
Funding body: Department of Health and Aged Care
Funding body | Department of Health and Aged Care |
---|---|
Project Team | Professor Murray Cairns, Professor Aaron Sverdlov, Professor Andrew Boyle, Professor Doan Ngo, Professor John Attia, Professor Clare Collins, Professor Christopher Reid, Prof Christopher Reid , Doctor William Reay, Dr Tracy Dudding-Byth, Dr Anastasia Mihaildou , Dr Anastasia Mihailidou, Doctor Tracy Dudding, Prof Andrew Boyle |
Scheme | MRFF - GHFM - Genomics Health Futures Mission |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2027 |
GNo | G2300029 |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | Y |
IMplementation and Prospective evAluation of dedicated Cardio-oncology services for prevention, monitoring and Treatment of CardioVascular Diseases in patients living with, through and beyond CANCER ($798,843
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Aaron Sverdlov, Professor Doan Ngo, Dr James Lynam, Dr Jarad Martin, Associate Professor Mathew George, AProf Mathew George , Prof John Wiggers , AProf Nicolette Hodyl , Professor John Wiggers, Dr NICOLETTE Hodyl, Prof Christopher Levi , Conjoint Professor Chris Levi, Ms Kerry Doyle, Dr Trent Williams, Kerry Doyle |
Scheme | Accelerated Research Implementation Grant |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2026 |
GNo | G2300071 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Improve Heart fAiLure Outcomes in Hunter New England LHD: I-HALO Project$244,750
Funding body: Astra Zeneca
Funding body | Astra Zeneca |
---|---|
Project Team | Prof Aaron Sverdlov, A/Prof Nicholas Collins, Prof Doan Ngo |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | N |
Hunter New England LHD Heart Failure Quality Improvement Initiative$52,800
Funding body: Novartis Pharmaceuticals Australia Pty Limited
Funding body | Novartis Pharmaceuticals Australia Pty Limited |
---|---|
Project Team | Prof Aaron Sverdlov, A/Prof Nicholas Collins, Prof Doan Ngo |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | N |
Bushfire smoke particulate and its implication on the heart and lung health in regional Australia$14,767
Funding body: Hunter New England Local Health District
Funding body | Hunter New England Local Health District |
---|---|
Project Team | Doctor Tatt Jhong Haw, Doctor Henry Gomez, Doctor Angeline Leong, Professor Aaron Sverdlov |
Scheme | John Hunter Hospital Charitable Trust Grant |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2300394 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Comorbidities associated with cardiovascular disease and death in patients receiving immune checkpoint inhibitors as part of their anticancer treatment: a retrospective study$5,060
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Professor Doan Ngo, Professor Aaron Sverdlov, Mr Joshua Bennetts |
Scheme | Travel Grants |
Role | Investigator |
Funding Start | 2023 |
Funding Finish | 2023 |
GNo | G2300497 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
20225 grants / $3,326,398
Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial$1,816,175
Funding body: Medical Research Futures Fund (MRFF)
Funding body | Medical Research Futures Fund (MRFF) |
---|---|
Project Team | Chow C, Hillis G, Brieger D, Sverdlov A, Atherton J, Thomas L, Lindley R, Ferguson C, Devereaux P, Conen D |
Scheme | International Clinical Trials Collaborations Program |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2027 |
GNo | |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | N |
Cardiovascular disease and cancer: identifying shared disease pathways and pharmacological management$1,033,379
Funding body: Department of Health and Aged Care
Funding body | Department of Health and Aged Care |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo, Professor Murray Cairns, Doctor Heather Lee, Associate Professor Nikki Verrills, Doctor Craig Gedye, Doctor Tatt Jhong Haw, Professor John Attia, Professor Michael Kelso, Dr Daniel Tillett, Dr James Lynam, Dr James Lynam, Associate Professor Anoop Enjeti, Dr Susan Dent, Kerry Doyle, OAM, Susan Dent, Kerry Doyle, Anoop Enjeti, Michael Kelso, Daniel Tillett |
Scheme | MRFF - Cardiovascular Health Mission - Cardiovascular Health |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2025 |
GNo | G2200136 |
Type Of Funding | C1300 - Aust Competitive - Medical Research Future Fund |
Category | 1300 |
UON | Y |
Sartorious Incucyte SX5 Live-Cell Analysis Instrument for high throughput screening of drugs for repurposing as chemotherapy in the treatment of cancer$400,000
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Doctor Michelle Brown, Professor Nikola Bowden, Karen Briscoe, Professor Doan Ngo, Dr Frank Reimann, Professor Aaron Sverdlov |
Scheme | Research Equipment Grant |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200706 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Better Access to Essential Cardiovascular Services in Regional, Rural and Remote Setting (BACS): Pilot study$66,360
Funding body: Novartis Pharmaceuticals Australia Pty Limited
Funding body | Novartis Pharmaceuticals Australia Pty Limited |
---|---|
Project Team | Prof Aaron Sverdlov, Prof Doan Ngo, A/Prof James Leitch |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2022 |
Funding Finish | 2025 |
GNo | |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | N |
Pharmacist reviews to reduce readmission rates and Improve adherence to guideline based therapy: A pilot study$10,484
Funding body: Hunter New England Local Health District
Funding body | Hunter New England Local Health District |
---|---|
Project Team | Doctor Trent Williams, Mr Cameron Robson, Professor Aaron Sverdlov |
Scheme | John Hunter Hospital Charitable Trust Grant |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2022 |
GNo | G2200585 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
202111 grants / $7,214,075
Anticoagulation for stroke prevention in patients with recent episodes of perioperative atrial fibrillation after noncardiac surgery - The ASPIRE-AF study$5,050,000
Funding body: Canadian Institutes of Health Research (CIHR)
Funding body | Canadian Institutes of Health Research (CIHR) |
---|---|
Project Team | Dr David Cohen, leading a team of 54 international Chief Investigators, including from Australia: Prof C Chow and A/Prof. A. Sverdlov |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2026 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
Improving cardiovascular health for Aboriginal and Torres Strait Islander people with cancer: towards optimal, cost-effective and equitable cardio-oncological care in Australia$999,974
Funding body: National Heart Foundation of Australia
Funding body | National Heart Foundation of Australia |
---|---|
Project Team | Prof Gail Garvey, Prof Alex Brown, A/Prof Aaron Sverdlov, Dr Abbey Diaz, Dr Mohsen Habibian, A/Prof Doan Ngo, Prof Euan Walpole, Prof Joan Cunningham, Prof Stephen Nicholls, Prof Eva Segelov |
Scheme | Cardio-Oncology Strategic Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2024 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
Improving cardiovascular health for people living with and beyond cancer$559,972
Funding body: National Heart Foundation of Australia
Funding body | National Heart Foundation of Australia |
---|---|
Project Team | Professor Aaron Sverdlov |
Scheme | Future Leader Fellowship |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2025 |
GNo | G2100634 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
Absence of Bisantrene Cardiotoxicity: Molecular Studies $400,636
Funding body: Race Oncology Ltd
Funding body | Race Oncology Ltd |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2022 |
GNo | G2100428 |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | Y |
MULTI-HEALTH: Co-creating a technology based multiple behaviour intervention for cancer survivors at increased risk of CVD$51,680
Funding body: World Cancer Research Fund International
Funding body | World Cancer Research Fund International |
---|---|
Project Team | Professor Mitch Duncan, Professor Annie Anderson, Annie Anderson, Prof ERICA James, P' Bogda Koczwara, Gary Wittert, Dr Camille Short, Camille Short, Professor Aaron Sverdlov, Bogda Koczwara, Professor Gary Wittert |
Scheme | International Regular Grant Programme |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2001157 |
Type Of Funding | C3500 – International Not-for profit |
Category | 3500 |
UON | Y |
MULTI-HEALTH: Co-creating a technology based multiple behaviour intervention for cancer survivors at increased risk of CVD$51,680
Funding body: Cancer Australia
Funding body | Cancer Australia |
---|---|
Project Team | Professor Mitch Duncan, Professor Annie Anderson, Prof ERICA James, P' Bogda Koczwara, Dr Camille Short, Professor Aaron Sverdlov, Professor Gary Wittert |
Scheme | Priority-driven Collaborative Cancer Research Scheme |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2101211 |
Type Of Funding | C1500 - Aust Competitive - Commonwealth Other |
Category | 1500 |
UON | Y |
Better Access to Essential Cardiovascular Services in Regional, Rural and Remote Setting (BACS): Pilot study$42,986
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Aaron Sverdlov, Dr James Leitch |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100908 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Cardio-Oncology Webinar Series$28,965
Funding body: Celgene Pty Ltd
Funding body | Celgene Pty Ltd |
---|---|
Scheme | Unrestricted Educational Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2022 |
GNo | |
Type Of Funding | C3111 - Aust For profit |
Category | 3111 |
UON | N |
A pilot study of Perindopril in combination with first line Ipilimumab and Nivolumab for patients with unresectable or metastatic melanoma.$18,182
Funding body: Hunter New England Local Health District
Funding body | Hunter New England Local Health District |
---|---|
Project Team | Professor Aaron Sverdlov, Dr Andre van der Westhuizen |
Scheme | John Hunter Hospital Charitable Trust Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100290 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Exploring appropriate pharmacotherapy for anxiety and depression in high-risk cardiovascular and cancer patients$5,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Hayley Croft, Professor Brian Kelly, Professor Doan Ngo, Professor Aaron Sverdlov |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100161 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Exploring the link between cardiovascular outcomes and mental health depression scores in cancer patients.$5,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Doan Ngo, Professor Aaron Sverdlov, Dr Bahador Asadi-Khansari |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100247 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20207 grants / $1,057,448
Can we treat cancer without breaking the heart? From cardiotoxicity to cardioprotection – reversing the impact of cancer therapies on cardiovascular health for cancer patients$736,786
Funding body: NSW Ministry of Health
Funding body | NSW Ministry of Health |
---|---|
Project Team | Professor Aaron Sverdlov, Doctor Anthony Proietto, Conjoint Professor Tom Walley, Professor John Attia, Professor John Wiggers, Professor Doan Ngo, Professor Rodney Scott, Gemma Figtree, Paul Burridge, Alex Lyon, Wilson Colucci, Daniel Lenihan |
Scheme | Early-Mid Career Researcher Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2022 |
GNo | G1901542 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Improving Outcomes Following Hospitalisation for Heart Failure in Regional and Remote NSW – the BEEM-HF Randomised Controlled Trial.$125,000
Funding body: NSW Ministry of Health
Funding body | NSW Ministry of Health |
---|---|
Project Team | Professor Aaron Sverdlov |
Scheme | Translational Research Grants Scheme (TRGS) |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2021 |
GNo | G2000974 |
Type Of Funding | C2300 – Aust StateTerritoryLocal – Own Purpose |
Category | 2300 |
UON | Y |
Cardio-oncology Strategic Initiative Grant$100,000
Funding body: Hunter Cancer Research Alliance (HCRA)
Funding body | Hunter Cancer Research Alliance (HCRA) |
---|---|
Project Team | A/Prof Aaron Sverdlov, A/Prof Doan Ngo, Dr Hiren Mandaliya, Dr Wojt Janowski, Dr Tatt Jhong Haw, Mr Conagh Kelly, Dr Maria Aslam, A/Prof Kathryn Skelding |
Scheme | Strategic Initiative Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | C3112 - Aust Not for profit |
Category | 3112 |
UON | N |
Better understanding of real-life incidence and treatment of iron deficiency and its impact on outcomes in heart failure patients in regional and rural Australia$57,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2022 |
GNo | G2000567 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Conference Sponsorship Grant$25,000
Funding body: Bristol-Myers Squibb Australia Pty Ltd
Funding body | Bristol-Myers Squibb Australia Pty Ltd |
---|---|
Project Team | A/Prof Doan Ngo |
Scheme | Conference Sponsorship Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | C3111 - Aust For profit |
Category | 3111 |
UON | N |
Preclinical testing of novel therapeutics to prevent chemotherapy-induced cardiotoxicity$12,162
Funding body: John Hunter Hospital Charitable Trust
Funding body | John Hunter Hospital Charitable Trust |
---|---|
Project Team | Professor Aaron Sverdlov |
Scheme | Research Funding |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2020 |
GNo | G2000325 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Event Sponsorship Grant - Australian Cardio-Oncology Conference$1,500
Funding body: Hunter Cancer Research Alliance (HCRA)
Funding body | Hunter Cancer Research Alliance (HCRA) |
---|---|
Project Team | A/Prof Doan Ngo |
Scheme | Event Sponsorship Grant |
Role | Lead |
Funding Start | 2020 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | C3120 - Aust Philanthropy |
Category | 3120 |
UON | N |
20197 grants / $270,889
Point-of-care NTproBNP testing to assist management of heart failure in primary practice$66,000
Funding body: Roche Diagnostics Pty Ltd
Funding body | Roche Diagnostics Pty Ltd |
---|---|
Project Team | A/Prof Aaron Sverdlov, A/Prof Doan Ngo, Prof Andrew Boyle, Dr James Leitch |
Scheme | Equipment Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | C3111 - Aust For profit |
Category | 3111 |
UON | N |
Better understanding of real-life incidence and treatment of iron deficiency and its impact on outcomes in heart failure patients in regional and rural Australia$60,000
Funding body: Vifor Pharma
Funding body | Vifor Pharma |
---|---|
Scheme | Project Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2021 |
GNo | |
Type Of Funding | C3111 - Aust For profit |
Category | 3111 |
UON | N |
Better understanding of mechanisms underlying heart failure due to obesity$50,000
Funding body: Royal Australasian College of Physicians
Funding body | Royal Australasian College of Physicians |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo |
Scheme | Foundation for High Blood Pressure Research Establishment Fellowship |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1801367 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
To further develop and test a new paradigm for the management of changing Heart Failure$50,000
Funding body: Biotronik Australia Pty Ltd
Funding body | Biotronik Australia Pty Ltd |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Andrew Boyle, Professor Doan Ngo |
Scheme | Entrepreneurs' Programme: Innovation Connections |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1901143 |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | Y |
Novel discovery of Sirtuin-3 isoforms in human cardiomyocytes$20,063
Funding body: John Hunter Hospital Charitable Trust
Funding body | John Hunter Hospital Charitable Trust |
---|---|
Project Team | Professor Aaron Sverdlov, Ms Amanda Croft, Professor Doan Ngo |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900118 |
Type Of Funding | C2400 – Aust StateTerritoryLocal – Other |
Category | 2400 |
UON | Y |
Assessment of vascular function using novel biomarkers in patients with adult congenital heart disease$19,826
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Nicholas Collins, Professor Aaron Sverdlov, Mr Conagh Kelly, Professor Andrew Boyle, Doctor Rachel Wong |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2022 |
GNo | G2000021 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Improving management and outcomes for patients with cancer therapy-induced cardiotoxicity$5,000
Funding body: National Heart Foundation of Australia
Funding body | National Heart Foundation of Australia |
---|---|
Project Team | Professor Aaron Sverdlov |
Scheme | 2018 Ministerial Award for Rising Stars in Cardiovascular Research |
Role | Lead |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900528 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
20187 grants / $735,747
Improving Outcomes Following Hospitalisation for Heart Failure in Regional and Remote NSW – the BEEM-HF Trial$479,376
Funding body: NSW Ministry of Health
Funding body | NSW Ministry of Health |
---|---|
Project Team | A/Prof Aaron Sverdlov, Prof Andrew Boyle, Dr James Leitch, Dr Maged William, Prof John Attia, Prof John Wiggers, Ms Dawn McIvor, Mr Lindsay Savage, Ms Julie Rutherford, A/Prof Doan Ngo |
Scheme | Translational Research Grant Scheme (TRGS) |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | C2220 - Aust StateTerritoryLocal - Other |
Category | 2220 |
UON | N |
To develop and test a new paradigm for management of changing Heart Failure disease treatment$99,371
Funding body: Biotronik Australia Pty Ltd
Funding body | Biotronik Australia Pty Ltd |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo, Professor Andrew Boyle |
Scheme | Entrepreneurs' Programme: Innovation Connections |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801209 |
Type Of Funding | C3100 – Aust For Profit |
Category | 3100 |
UON | Y |
Predicting tOxicity for Myeloma Therapy (PrOMT)$50,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Anoop Enjeti, Doctor Wojt Janowski, Doctor Chen Chen Jiang, Professor Aaron Sverdlov |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1900030 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Health Economic analyses for BEEM-HF trial$40,000
Funding body: Hunter New England Local Health District
Funding body | Hunter New England Local Health District |
---|---|
Project Team | A/Prof Aaron Sverdlov, A/Prof Andrew Searles |
Scheme | 2018 HNE MRSP |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | Other Public Sector - Local |
Category | 2OPL |
UON | N |
Identification of novel biomarkers to predict early onset chemotherapy-induced cardiovascular toxicities$37,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Professor Doan Ngo, Professor Aaron Sverdlov, Associate Professor Anoop Enjeti, Prof Philip Rowlings, Associate Professor Anthony Proietto |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801448 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Determining the mechanisms of myocardial infarction induced cardiac fibrosis: what role does fibulin-3 play?$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Lucy Murtha, Professor Andrew Boyle, Professor Doan Ngo, Professor Aaron Sverdlov |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801370 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Statistical analyses for BEEM-HF trial$5,000
Funding body: Hunter New England Local Health District
Funding body | Hunter New England Local Health District |
---|---|
Project Team | A/Prof Aaron Sverdlov; CREDITTS group |
Scheme | HRTC |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2020 |
GNo | |
Type Of Funding | Other Public Sector - Local |
Category | 2OPL |
UON | N |
20177 grants / $746,120
Bench-to-bedside approach to improving management and outcomes for patients with heart failure$529,120
Funding body: National Heart Foundation of Australia
Funding body | National Heart Foundation of Australia |
---|---|
Project Team | Professor Aaron Sverdlov |
Scheme | Future Leader Fellowship |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2021 |
GNo | G1700785 |
Type Of Funding | C1700 - Aust Competitive - Other |
Category | 1700 |
UON | Y |
Cardiometabolic research program$100,000
Funding body: Hunter New England Local Health District
Funding body | Hunter New England Local Health District |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | G1701207 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000
Funding body: National Heart Foundation of Australia
Funding body | National Heart Foundation of Australia |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo, Professor John Horowitz, AM |
Scheme | Vanguard Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | G1701324 |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | Y |
Equipment Grant - Vevo 1100 Imaging System$20,000
Funding body: Faculty of Health and Medicine, University of Newcastle
Funding body | Faculty of Health and Medicine, University of Newcastle |
---|---|
Scheme | Faculty Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
Assessing the feasibility of angiotensin receptor blocker/neprilysin inhibitor (ARNI) in reducing the progression of aortic valve stenosis$10,000
Funding body: Universtiy of Newcastle
Funding body | Universtiy of Newcastle |
---|---|
Scheme | Linkage Pilot Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
EMCR EQUIPMENT GRANT$10,000
Funding body: Hunter Medical Research Institute (HMRI)
Funding body | Hunter Medical Research Institute (HMRI) |
---|---|
Scheme | Unknown |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
Dissecting hypertrophic pathways in obesity-mediated heart failure$2,000
Funding body: Faculty of Health and Medicine Pilot Grant University of Newcastle
Funding body | Faculty of Health and Medicine Pilot Grant University of Newcastle |
---|---|
Scheme | UON Faculty of Health and Medicine Pilot Grant |
Role | Lead |
Funding Start | 2017 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
20165 grants / $224,516
Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000
Funding body: National Heart Foundation of Australia
Funding body | National Heart Foundation of Australia |
---|---|
Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz |
Scheme | Vanguard Grant |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
Regulators of the novel anti-angiogenic isoform: VEGF-A165b in obesity$60,000
Funding body: Diabetes Australia
Funding body | Diabetes Australia |
---|---|
Project Team | Associate Professor Doan Ngo (Lead), Associate Professor Aaron Sverdlov |
Scheme | Research Grant |
Role | Investigator |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
Early detection of chemotherapy-induced cardiomyopathy$50,000
Funding body: Royal Australasian College of Physicians
Funding body | Royal Australasian College of Physicians |
---|---|
Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo |
Scheme | Research Establishment Award |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2018 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
Metabolic heart disease: markers and mechanisms$25,000
Funding body: Rebecca L Cooper Medical Research Foundation Ltd
Funding body | Rebecca L Cooper Medical Research Foundation Ltd |
---|---|
Project Team | Professor Aaron Sverdlov, Professor Doan Ngo |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2017 |
GNo | G1701494 |
Type Of Funding | C3200 – Aust Not-for Profit |
Category | 3200 |
UON | Y |
Are mitochondrial reactive oxygen species key mediators of metabolic syndrome-induced heart disease$14,516
Funding body: The University of Adelaide
Funding body | The University of Adelaide |
---|---|
Scheme | Shared |
Role | Lead |
Funding Start | 2016 |
Funding Finish | 2016 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
20152 grants / $470,000
Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$450,000
Funding body: The University of Sydney
Funding body | The University of Sydney |
---|---|
Scheme | - |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
Start up grant$20,000
Funding body: University of Adelaide
Funding body | University of Adelaide |
---|---|
Scheme | Unknown |
Role | Lead |
Funding Start | 2015 |
Funding Finish | 2015 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
20141 grants / $130,000
Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$130,000
Funding body: American Heart Association
Funding body | American Heart Association |
---|---|
Scheme | Postdoctoral Fellowship |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2015 |
GNo | |
Type Of Funding | International - Competitive |
Category | 3IFA |
UON | N |
20131 grants / $3,100
Keystone Symposium Travel Grant$3,100
Funding body: The University of Adelaide
Funding body | The University of Adelaide |
---|---|
Scheme | Travel Grant |
Role | Lead |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
20125 grants / $481,107
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$435,257
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | A/Prof Aaron Sverdlov |
Scheme | Early Career Fellowships |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Aust Competitive - Commonwealth |
Category | 1CS |
UON | N |
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$20,000
Funding body: Royal Australasian College of Physicians
Funding body | Royal Australasian College of Physicians |
---|---|
Scheme | Margorie Hooper Fellowship |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2013 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$15,000
Funding body: Medtronic
Funding body | Medtronic |
---|---|
Scheme | Postdoctoral project funding |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Donation - Aust Non Government |
Category | 3AFD |
UON | N |
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$10,000
Funding body: Boston Scientific
Funding body | Boston Scientific |
---|---|
Scheme | Postdoctoral project funding |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2017 |
GNo | |
Type Of Funding | Donation - Aust Non Government |
Category | 3AFD |
UON | N |
Travel Award$850
Funding body: Seahorse Bioscience
Funding body | Seahorse Bioscience |
---|---|
Scheme | Travel Award |
Role | Lead |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | |
Type Of Funding | International - Non Competitive |
Category | 3IFB |
UON | N |
20092 grants / $4,500
AHA 2009 Traveling Fellowship$3,000
Funding body: Cardiac Society of Australia and NewZealand
Funding body | Cardiac Society of Australia and NewZealand |
---|---|
Scheme | Travelling Fellowship |
Role | Lead |
Funding Start | 2009 |
Funding Finish | 2009 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
Small Grant$1,500
Funding body: Heart Foundation
Funding body | Heart Foundation |
---|---|
Scheme | E O Myers Trust Fund Grant |
Role | Lead |
Funding Start | 2009 |
Funding Finish | 2009 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
20082 grants / $61,600
Pathogenesis of aortic valve sclerosis$55,000
Funding body: CVL - Pfiser
Funding body | CVL - Pfiser |
---|---|
Scheme | Unknown |
Role | Lead |
Funding Start | 2008 |
Funding Finish | 2008 |
GNo | |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | N |
Equipment grant$6,600
Funding body: Heart Foundation
Funding body | Heart Foundation |
---|---|
Scheme | J Fund Grant |
Role | Lead |
Funding Start | 2008 |
Funding Finish | 2008 |
GNo | |
Type Of Funding | Aust Competitive - Non Commonwealth |
Category | 1NS |
UON | N |
20051 grants / $85,000
Pathogenesis of aortic valve stenosis$85,000
Funding body: The University of Adelaide
Funding body | The University of Adelaide |
---|---|
Scheme | Faculty of Health Sciences Divisional PhD Scholarship |
Role | Lead |
Funding Start | 2005 |
Funding Finish | 2010 |
GNo | |
Type Of Funding | Internal |
Category | INTE |
UON | N |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2021 | PhD | Impact of Pharmacist Involvement in the Transitional Care of High-Risk Cardiovascular patients for Medication Reconciliation, Medication Education, and Postdischarge Call-Backs | PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2021 | PhD | Mechanisms and Benefits of Rhythm Control in Atrial Fibrillation | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2020 | PhD | Can Improving Redox State in Obesity Protect the Heart from Failure and the Gut from Cancer? | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2020 | PhD | Improving Cardiovascular Outcomes for Cancer Patients and Survivors: Focus on Novel Biomarkers for Risk Stratification | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2019 | PhD | Understanding Anthracycline-Induced Cardiotoxicity: Mechanisms, Detection and Treatment | PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2019 | PhD | Improving Outcomes following Hospitalisation for Heart Failure in Regional and Remote NSW-the BEEM-HF Study | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Principal Supervisor |
2018 | PhD | Early Detection of Cardiotoxicity from Chemotherapy | PhD (Pharmacy), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2017 | Post-Doctoral Fellowship | Heart Failure pathophysiology and novel biomarkers | Medical Science, University of Adelaide | Co-Supervisor |
2016 | PhD | The Use of N-acetylcysteine and Ramipril to improve clinical outcomes in Tako Tsubo Cardiomyopathy | Medical Science, University of Adelaide | Co-Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2022 | PhD | Heart Failure Outcomes in Hunter New England Area between 2005-2014 | PhD (Medicine), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2018 | Post-Doctoral Fellowship | Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity? | Medical Science, School of Medicine & Public Health, Faculty of Health & Medicine, University of Newcastle | Australia | Principal Supervisor |
2018 | Honours | Heart failure: novel biomarkers | Medical Science, University of Adelaide | Co-Supervisor |
News
News • 2 Feb 2021
Today’s cancer patients need not be tomorrow’s cardiovascular patients
Today’s cancer patient may be tomorrow’s cardiac patient, with almost a third of people who survive cancer developing cardiovascular disease (CVD).
News • 7 May 2020
Hearty success in NSW Medical Research Cardiovascular grants
Heart disease kills one person every 12 minutes in Australia, and is still the leading cause of death globally. Despite enormous improvements in health outcomes over the years, heart disease is still one of the biggest health burdens on our economy.
News • 7 Nov 2018
Heart failure researcher named 2018 rising star
Associate Professor Aaron Sverdlov has been recognised with the 2018 Ministerial Award for Rising Stars in Cardiovascular Research.
News • 11 Dec 2017
Newcastle researchers awarded $750,000 to help heart health
Six Hunter researchers will focus on helping Australians have better heart health by investigating the causes, treatment and prevention of heart disease, after securing more than $750,000 in funding from the Heart Foundation.
Professor Aaron Sverdlov
Position
Director of Heart Failure
Cardio-Metabolic and Heart Failure Groups
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Contact Details
aaron.sverdlov@newcastle.edu.au | |
Phone | (02) 4042 0725 |
Links |
Research Networks Research Networks Research Networks |